A New Therapeutic Strategy for Malaria: Targeting T Cell Exhaustion

Overview

Journal Nat Immunol

Date 2012 Jan 21

PMID 22261959

Citations 12

Authors

Gordon J Freeman

Arlene H Sharpe

Affiliations

Soon will be listed here.

Citing Articles

Advances in understanding the role of immune checkpoint LAG-3 in tumor immunity: a comprehensive review.

Luo Y, Cai X, Yang B, Lu F, Yi C, Wu G Front Oncol. 2024; 14:1402837.

PMID: 39252941 PMC: 11381248. DOI: 10.3389/fonc.2024.1402837.

Chronic malaria exposure is associated with inhibitory markers on T cells that correlate with atypical memory and marginal zone-like B cells.

Mitchell R, Ubillos I, Requena P, Campo J, Ome-Kaius M, Hanieh S Clin Exp Immunol. 2024; 216(2):172-191.

PMID: 38387476 PMC: 11036110. DOI: 10.1093/cei/uxae015.

Exhausted CD4 T Cells during Malaria Exhibit Reduced mTORc1 Activity Correlated with Loss of T-bet Expression.

Villegas-Mendez A, Khandelwal G, McGowan L, Dookie R, Haley M, George C J Immunol. 2020; 205(6):1608-1619.

PMID: 32817333 PMC: 7477746. DOI: 10.4049/jimmunol.2000450.

First-in-class immune-modulating small molecule Icaritin in advanced hepatocellular carcinoma: preliminary results of safety, durable survival and immune biomarkers.

Fan Y, Li S, Ding X, Yue J, Jiang J, Zhao H BMC Cancer. 2019; 19(1):279.

PMID: 30922248 PMC: 6437929. DOI: 10.1186/s12885-019-5471-1.

Control of NK Cell Activation by Immune Checkpoint Molecules.

Beldi-Ferchiou A, Caillat-Zucman S Int J Mol Sci. 2017; 18(10).

PMID: 29023417 PMC: 5666811. DOI: 10.3390/ijms18102129.

References

Barber D, Wherry E, Masopust D, Zhu B, Allison J, Sharpe A . Restoring function in exhausted CD8 T cells during chronic viral infection. Nature. 2005; 439(7077):682-7. DOI: 10.1038/nature04444. View

Blackburn S, Shin H, Nicholas Haining W, Zou T, Workman C, Polley A . Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol. 2008; 10(1):29-37. PMC: 2605166. DOI: 10.1038/ni.1679. View

Porichis F, Kwon D, Zupkosky J, Tighe D, McMullen A, Brockman M . Responsiveness of HIV-specific CD4 T cells to PD-1 blockade. Blood. 2011; 118(4):965-74. PMC: 3148173. DOI: 10.1182/blood-2010-12-328070. View

Butler N, Moebius J, Pewe L, Traore B, Doumbo O, Tygrett L . Therapeutic blockade of PD-L1 and LAG-3 rapidly clears established blood-stage Plasmodium infection. Nat Immunol. 2011; 13(2):188-95. PMC: 3262959. DOI: 10.1038/ni.2180. View

Freeman G, Wherry E, Ahmed R, Sharpe A . Reinvigorating exhausted HIV-specific T cells via PD-1-PD-1 ligand blockade. J Exp Med. 2006; 203(10):2223-7. PMC: 2118103. DOI: 10.1084/jem.20061800. View

Wherry E, Ha S, Kaech S, Nicholas Haining W, Sarkar S, Kalia V . Molecular signature of CD8+ T cell exhaustion during chronic viral infection. Immunity. 2007; 27(4):670-84. DOI: 10.1016/j.immuni.2007.09.006. View

Fourcade J, Sun Z, Benallaoua M, Guillaume P, Luescher I, Sander C . Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J Exp Med. 2010; 207(10):2175-86. PMC: 2947081. DOI: 10.1084/jem.20100637. View

Hafalla J, Silvie O, Matuschewski K . Cell biology and immunology of malaria. Immunol Rev. 2011; 240(1):297-316. DOI: 10.1111/j.1600-065X.2010.00988.x. View

Brahmer J, Drake C, Wollner I, Powderly J, Picus J, Sharfman W . Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010; 28(19):3167-75. PMC: 4834717. DOI: 10.1200/JCO.2009.26.7609. View

10.

Hodi F, ODay S, Mcdermott D, Weber R, Sosman J, Haanen J . Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363(8):711-23. PMC: 3549297. DOI: 10.1056/NEJMoa1003466. View

11.

Keir M, Butte M, Freeman G, Sharpe A . PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008; 26:677-704. PMC: 10637733. DOI: 10.1146/annurev.immunol.26.021607.090331. View

12.

Jin H, Anderson A, Tan W, West E, Ha S, Araki K . Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection. Proc Natl Acad Sci U S A. 2010; 107(33):14733-8. PMC: 2930455. DOI: 10.1073/pnas.1009731107. View

13.

Goldberg M, Drake C . LAG-3 in Cancer Immunotherapy. Curr Top Microbiol Immunol. 2010; 344:269-78. PMC: 4696019. DOI: 10.1007/82_2010_114. View

14.

Brooks D, Ha S, Elsaesser H, Sharpe A, Freeman G, Oldstone M . IL-10 and PD-L1 operate through distinct pathways to suppress T-cell activity during persistent viral infection. Proc Natl Acad Sci U S A. 2008; 105(51):20428-33. PMC: 2629263. DOI: 10.1073/pnas.0811139106. View

15.

Matsuzaki J, Gnjatic S, Mhawech-Fauceglia P, Beck A, Miller A, Tsuji T . Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc Natl Acad Sci U S A. 2010; 107(17):7875-80. PMC: 2867907. DOI: 10.1073/pnas.1003345107. View